Healthcare Industry News:  cord blood 

Biopharmaceuticals Regenerative Medicine Personnel

 News Release - April 10, 2006

ViaCell Announces Executive Appointments in its Reproductive Health Business

James Corbett Named President of ViaCell Reproductive Health Mary Thistle Named Senior Vice President, Business Development, ViaCell Reproductive Health

CAMBRIDGE, Mass., April 10 (HSMN NewsFeed) -- ViaCell, Inc. (Nasdaq: VIAC ) today announced that Mr. James Corbett has joined the Company in the newly created position, President of ViaCell Reproductive Health. In this position, Mr. Corbett will have overall responsibility for ViaCell's Reproductive Health business, including sales and marketing of ViaCord®, its product to preserve umbilical cord blood for related use. In addition, he will have responsibility for the potential introduction of new products to the marketplace. Mr. Corbett will report to Marc D. Beer, President and Chief Executive Officer of ViaCell.

ViaCell also announced today the appointment of Mary T. Thistle from Senior Vice President and General Manager of ViaCell Reproductive Health to the newly created position Senior Vice President, Business Development, ViaCell Reproductive Health. In this new role, Ms. Thistle will have responsibility for identifying, negotiating and integrating new products, technologies and businesses into ViaCell Reproductive Health.

"I believe this is a significant time of growth for our organization and I'm delighted to have these talented executives leading our efforts to expand the Reproductive Health business," said Mr. Beer. "Jim is a seasoned healthcare executive with a proven track record in building successful global businesses, and I look forward to the contributions he will make to further advance our commercial business. In addition, Mary's leadership has positioned the business extremely well for future growth, and she is credited with many accomplishments, including growing the business consistently year-over-year. I am confident she will drive new growth opportunities."

Mr. Corbett joins ViaCell with over twenty-two years of healthcare experience and extensive knowledge in developing and implementing strategic plans to drive commercial growth in rapidly growing healthcare products, integrating new products and businesses as growth strategies, and successfully negotiating partnerships with industry leaders.

He held a variety of sales and marketing positions at Abbott Laboratories, Inc., including Worldwide Marketing Manager for Abbott Diagnostics Immunoassay Systems and Regional Manager of Abbott Diagnostics. From Abbott, he became Corporate Vice President of Worldwide Marketing at BioChem Immunosystems, a division of BioChem Pharma. After successfully developing and implementing a strategic plan for BioChem's diagnostic business, he co-founded CADx Systems, a company focused on the oncology market with products addressing breast, lung and colon cancer. At CADx, he held the position Executive Vice President and Director and was responsible for worldwide sales and marketing, technical support and business development. Following the 2004 acquisition of CADx by iCAD, Inc., Mr. Corbett was named Chief Commercial Officer where he developed and implemented the strategic business plan. As a result, the business achieved significant revenue growth, improved gross margins and profitability. Mr. Corbett received a B.Sc. from The University of Massachusetts, Amherst.

Ms. Thistle served as Senior Vice President, General Manager, ViaCell Reproductive Health since October 2004 where she was responsible for all aspects of the Reproductive Health business including sales, marketing, customer service and laboratory operations. Prior to that, she was Vice President, ViaCord Operations and also held the position of Vice President of Financial and Corporate Planning and Treasurer since joining ViaCell in October 2000. Prior to joining ViaCell, Ms. Thistle held a variety of positions in finance, auditing, and operations at several publicly traded companies. Ms. Thistle has a B.S. in Accounting from the University of Massachusetts.

About ViaCell, Inc.

ViaCell is a biotechnology company focused on enabling the widespread use of human cells as medicine. The Company is developing a pipeline of proprietary stem cell product candidates intended to address cancer, cardiac disease, and diabetes. CB001, its lead cord blood derived stem cell therapy product candidate, is being developed for hematopoietic stem cell transplantation in patients affected by a variety of cancers. In addition to its therapeutic development programs, ViaCell's Reproductive Health Business commercializes ViaCord®, a product that offers expecting families the option of preserving their baby's umbilical cord blood. The Company is working to leverage its commercial infrastructure and product development capabilities by developing ViaCyte(SM), its investigational product intended to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. ViaCell is headquartered in Cambridge, Massachusetts with a processing and storage facility in Kentucky and additional research and development operations in Singapore.

This press release contains forward-looking statements regarding the Company's potential growth. These statements are based on management's current expectations. The Company's growth is subject to a number of risks and uncertainties. Factors which could cause actual results to differ materially from the Company's current expectations include, but are not limited to: the Company's overall financial performance, the impact of competition in the umbilical cord preservation industry, the impact of any potential adverse outcome in pending patent infringement litigation related to the cord blood preservation business, any other unexpected material issues, delays or failures in the collection, processing or storage of umbilical cord blood by the Company, and fluctuations in the level and timing of expenses as a result of difficulties or delays in the development of the Company's product candidates or in bringing new products to the marketplace. Currently, the Company's product candidates are at an early stage of development. There can be no assurance that the Company will be successful in its efforts to develop these or other products. For more information on the risks and uncertainties associated with the Company, its financial performance, its products and programs, and pending litigation, see the factors set forth under the heading "Risk Factors That May Affect Results" in the Company's Annual Report on Form 10-K filed on March 31, 2006, which is on file with the Securities and Exchange Commission and which factors are incorporated herein by reference. ViaCell does not undertake any obligation to update forward-looking statements.

ViaCell® and ViaCord® are federally registered trademarks and ViaCyte(SM) is a service mark of ViaCell, Inc.

Investors: Justine E. Koenigsberg, Senior Director, Corporate Communications, ViaCell, Inc., (617) 914-3494

Media: Justin Jackson, jjackson@burnsmc.com , or Jason Farber, jfarber@burnsmc.com , both of Burns McClellan, (212) 213-0006


Source: ViaCell

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.